MAOB and Parkinson disease: It is widely reported in scientific literature that the MAO-B activity appears to increase with aging as well as in patients affected by neurodegenerative conditions including Parkinson’s disease and Alzheimer’s disease, thus explaining the administration of MAO-B inhibitors to treat the abovementioned diseases [10].